Notably: BPC-157, KPV, MOTs-C, Emideltide (DSIP), Epitalon, Semax (heptapeptide) and TB-500 are among those expected to be reviewed in July 2026 Other substances, including Cathelicidin LL-37, Dihexa Acetate, PEG-MGF, GHK-Cu and Melanotan II, are under consideration for review by early 2027 Non-injectable GHK-Cu is following a slightly different path, with separate evaluation anticipated before February 2027
Comparison Both work on fat metabolism
This means you feel satisfied longer after eating and are less likely to overeat
However, each platform operates under different regulatory and clinical oversight models
Once approved, youll receive weekly injections and ongoing support from our team to help you succeed
However, one study into the use of one of these medications, Mounjaro, found that approximately 500,000 people in the UK have used the drug privately for weight loss since 2023